Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient

Kuan Pin Su; Winston W. Shen; Shih Yi Huang

doi:10.1016/S0924-977X(01)00098-0

Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient

Kuan Pin Su, Winston W. Shen, Shih Yi Huang

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Because of the potential adverse events and teratogenesis of antipsychotic drugs, it is important to find a safe and effective treatment for pregnant women with severe mental illness. The membrane hypothesis of schizophrenia provides a rationale to treat symptoms of schizophrenia with omega-3 PUFAs. We report a 30-year-old married woman with chronic schizophrenia, who experienced an episode of acute exacerbation of psychotic symptoms during pregnancy. After entering into an open trial of omega-3 PUFAs monotherapy, she showed a dramatic improvement in both positive and negative symptoms of schizophrenia and a significant increase of omega-3 PUFA composition in erythrocyte membrane. There were no adverse effects in this treatment. Thus, omega-3 PUFAs could be both beneficial and therapeutic to pregnant schizophrenic women.

Original language	English
Pages (from-to)	295-299
Number of pages	5
Journal	European Neuropsychopharmacology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/S0924-977X(01)00098-0
Publication status	Published - 2001

Keywords

Docosahexaenoic acid (DHA)
Ecosapentaenoic acid (EPA)
Omega-3 polyunsaturated fatty acids (PUFAs)
Pregnancy
Schizophrenia
Teratogenesis

ASJC Scopus subject areas

Pharmacology
Neurology
Clinical Neurology
Psychiatry and Mental health
Biological Psychiatry
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0924-977X(01)00098-0

Cite this

@article{29a5ddbcb6aa49b188a3d4c1c0c3b908,

title = "Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient",

abstract = "Because of the potential adverse events and teratogenesis of antipsychotic drugs, it is important to find a safe and effective treatment for pregnant women with severe mental illness. The membrane hypothesis of schizophrenia provides a rationale to treat symptoms of schizophrenia with omega-3 PUFAs. We report a 30-year-old married woman with chronic schizophrenia, who experienced an episode of acute exacerbation of psychotic symptoms during pregnancy. After entering into an open trial of omega-3 PUFAs monotherapy, she showed a dramatic improvement in both positive and negative symptoms of schizophrenia and a significant increase of omega-3 PUFA composition in erythrocyte membrane. There were no adverse effects in this treatment. Thus, omega-3 PUFAs could be both beneficial and therapeutic to pregnant schizophrenic women.",

keywords = "Docosahexaenoic acid (DHA), Ecosapentaenoic acid (EPA), Omega-3 polyunsaturated fatty acids (PUFAs), Pregnancy, Schizophrenia, Teratogenesis",

author = "Su, {Kuan Pin} and Shen, {Winston W.} and Huang, {Shih Yi}",

note = "Funding Information: The work was supported by the grants NSC 89-2320-B-038-046 from the National Science Council, TMC88-Y05-A121 from the Taipei Medical University, and China Chemical and Pharmaceutical Company, Taipei, Taiwan. The authors thank Li-Chia Chen, Tsung-Ta Liu, Chin-Hua Liu, Hui-Ting Yang and Hsin Chein for data collection. Copyright: Copyright 2007 Elsevier B.V., All rights reserved.",

year = "2001",

doi = "10.1016/S0924-977X(01)00098-0",

language = "English",

volume = "11",

pages = "295--299",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient

AU - Su, Kuan Pin

AU - Shen, Winston W.

AU - Huang, Shih Yi

N1 - Funding Information: The work was supported by the grants NSC 89-2320-B-038-046 from the National Science Council, TMC88-Y05-A121 from the Taipei Medical University, and China Chemical and Pharmaceutical Company, Taipei, Taiwan. The authors thank Li-Chia Chen, Tsung-Ta Liu, Chin-Hua Liu, Hui-Ting Yang and Hsin Chein for data collection. Copyright: Copyright 2007 Elsevier B.V., All rights reserved.

PY - 2001

Y1 - 2001

N2 - Because of the potential adverse events and teratogenesis of antipsychotic drugs, it is important to find a safe and effective treatment for pregnant women with severe mental illness. The membrane hypothesis of schizophrenia provides a rationale to treat symptoms of schizophrenia with omega-3 PUFAs. We report a 30-year-old married woman with chronic schizophrenia, who experienced an episode of acute exacerbation of psychotic symptoms during pregnancy. After entering into an open trial of omega-3 PUFAs monotherapy, she showed a dramatic improvement in both positive and negative symptoms of schizophrenia and a significant increase of omega-3 PUFA composition in erythrocyte membrane. There were no adverse effects in this treatment. Thus, omega-3 PUFAs could be both beneficial and therapeutic to pregnant schizophrenic women.

AB - Because of the potential adverse events and teratogenesis of antipsychotic drugs, it is important to find a safe and effective treatment for pregnant women with severe mental illness. The membrane hypothesis of schizophrenia provides a rationale to treat symptoms of schizophrenia with omega-3 PUFAs. We report a 30-year-old married woman with chronic schizophrenia, who experienced an episode of acute exacerbation of psychotic symptoms during pregnancy. After entering into an open trial of omega-3 PUFAs monotherapy, she showed a dramatic improvement in both positive and negative symptoms of schizophrenia and a significant increase of omega-3 PUFA composition in erythrocyte membrane. There were no adverse effects in this treatment. Thus, omega-3 PUFAs could be both beneficial and therapeutic to pregnant schizophrenic women.

KW - Docosahexaenoic acid (DHA)

KW - Ecosapentaenoic acid (EPA)

KW - Omega-3 polyunsaturated fatty acids (PUFAs)

KW - Pregnancy

KW - Schizophrenia

KW - Teratogenesis

UR - http://www.scopus.com/inward/record.url?scp=0034893932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034893932&partnerID=8YFLogxK

U2 - 10.1016/S0924-977X(01)00098-0

DO - 10.1016/S0924-977X(01)00098-0

M3 - Article

C2 - 11532384

AN - SCOPUS:0034893932

SN - 0924-977X

VL - 11

SP - 295

EP - 299

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

IS - 4

ER -

Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this